6533b856fe1ef96bd12b1ce6

RESEARCH PRODUCT

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Dario FerreroMarco SantoroChiara ElenaCarmen FavaMatteo DraganiGiacomo AndreaniGiuseppe SaglioMichele CedroneGiovanna Rege-cambrinPatrizia PregnoElisabetta Abruzzese

subject

OncologyDrugAdultMaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsDisease-Free Survival03 medical and health sciencesMyelogenous0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorsmedia_commonWithholding TreatmentDose-Response Relationship Drugbusiness.industryMyeloid leukemiaHematologyProtein-Tyrosine Kinasesmedicine.diseaseDiscontinuationLeukemiaPyrimidinesOncologyWithholding Treatment030220 oncology & carcinogenesisMolecular ResponseImatinib MesylateFemalebusinessTyrosine kinase030215 immunologyFollow-Up Studies

description

Discontinuation of tyrosine kinase inhibitors (TKIs) therapy is now feasible for patients with chronic myeloid leukemia (CML) with deep and longstanding molecular response (MR 4/4.5); around 40–60%...

yearjournalcountryeditionlanguage
2019-06-05Leukemialymphoma
10.1080/10428194.2019.1622103https://pubmed.ncbi.nlm.nih.gov/31161827